1. Home
  2. VYGR vs SCII Comparison

VYGR vs SCII Comparison

Compare VYGR & SCII Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Voyager Therapeutics Inc.

VYGR

Voyager Therapeutics Inc.

N/A

Current Price

$3.09

Market Cap

216.3M

Sector

Health Care

ML Signal

N/A

SCII

SC II Acquisition Corp. Class A ordinary share

N/A

Current Price

$10.12

Market Cap

251.5M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
VYGR
SCII
Founded
2013
2025
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
216.3M
251.5M
IPO Year
2015
2025

Fundamental Metrics

Financial Performance
Metric
VYGR
SCII
Price
$3.09
$10.12
Analyst Decision
Strong Buy
Analyst Count
2
0
Target Price
$16.50
N/A
AVG Volume (30 Days)
404.5K
47.0K
Earning Date
05-08-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$10,135,000.00
N/A
Revenue This Year
$34.04
N/A
Revenue Next Year
$7.92
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.94
$9.93
52 Week High
$5.55
$10.15

Technical Indicators

Market Signals
Indicator
VYGR
SCII
Relative Strength Index (RSI) 42.00 56.96
Support Level $2.95 $9.95
Resistance Level $3.30 N/A
Average True Range (ATR) 0.14 0.01
MACD -0.03 0.00
Stochastic Oscillator 13.19 70.00

Price Performance

Historical Comparison
VYGR
SCII

About VYGR Voyager Therapeutics Inc.

Voyager Therapeutics Inc is a biotechnology company to leverage the power of human genetics to modify the course of and ultimately cure neurological diseases. Its pipeline includes programs for Alzheimer's disease, or AD; Friedreich's ataxia, or FA; Parkinson's disease, or PD; and multiple other diseases of the central nervous system, or CNS. Many of its programs are derived from its TRACER (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) adeno-associated virus, or AAV, capsid discovery platform, which the company has used to generate novel capsids, or TRACER Capsids, and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous, or IV, dosing. Its segment is developing and commercializing genetic medicine.

About SCII SC II Acquisition Corp. Class A ordinary share

SC II Acquisition Corp is a blank check company. The company was incorporated for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.

Share on Social Networks: